LivaNova (NSDQ:LIVN) said today that it won national reimbursement through Japan’s Ministry of Health, Labour and Welfare for its Perceval sutureless aortic heart valve intended to treat aortic valve disease.
The London-based company said that the elastic Perceval valve’s sutureless design allows it to achieve optimal effective orifice area for improved hemodynamics. The company said that procedures utilizing the Perceval valve result in shorter intensive care unit stays, reduced ventilation time and less blood transfusions.
“With national reimbursement for Perceval, an innovative and trusted valve platform, we can provide patients and clinicians in Japan with an innovative and effective option for aortic heart valve replacement,” LivaNova Japan prez Noriaki Kawana said in a press release.
LivaNova won Japanese clearance for the Perceval valve last June. The system won CE Mark approval in the European Union in 2011 and FDA clearance in 2016.
“We are committed to enhancing patient care around the world. Perceval has a strong history of positive safety and efficacy outcomes, and we are pleased to bring this valve as a treatment option to patients in Japan,” LivaNova International prez Roy Khoury said in a prepared statement.
